Graft rejection in patients with severe aplastic anemia (SAA) following allogeneic hematopoietic stem cell transplantation (HSCT) is strongly associated with a large number of prior transfusions and with prolonged disease duration before transplant. We retrospectively analyzed the outcomes and the factor affecting these multitransfused SAA patients, who had received triple agent immunosuppression and high doses of stem cells to overcome rejection. In total, 113 patients with SAA who had a median 16 months (range 1-216) of disease duration were transplanted using HLA-matched sibling donors after conditioning with cyclophosphamide (CY), procarbazine (PCB), and ATG. Graft failure occurred in 16 of the eligible 113 patients, and with a median follow-up of 30 months (range, 1-80), probability of overall rejection was 15%. Specifically, the multitransfused patients who received high doses of stem cells with T-cell depletion showed the lowest rejection rate, 5.6%, compared with 30.3% in multitransfused patients with bone marrow stem cells alone (P ¼ 0.0310). Disease duration (P ¼ 0.0338) and the number of infused CD34+cells (P ¼ 0.0101) were associated with a high risk of graft rejection on multivariate analysis. ABO mismatch and the number of CD34+ cells were significant factors in the incidence of acute graft-versus-host-disease (GVHD). The incidence of chronic GVHD among patients with sustained engraftment was 13/109 (11.9%). With the same follow-up period, probability of disease-free survival for the entire group of patients at 6 years was 89% and the only factor associated with long-term survival was rejection (P ¼ 0.0241). These results suggest that allogeneic HSCT conditioned with triple agent immunosuppression, and specifically with high-dose stem cell return is probably an effective treatment for successful engraftment in SAA patients with a high risk of rejection.
Graft rejection in patients with severe aplastic anemia (SAA) following allogeneic hematopoietic stem cell transplantation (HSCT) is strongly associated with a large number of prior transfusions and with prolonged disease duration before transplant. We retrospectively analyzed the outcomes and the factor affecting these multitransfused SAA patients, who had received triple agent immunosuppression and high doses of stem cells to overcome rejection. In total, 113 patients with SAA who had a median 16 months (range 1-216) of disease duration were transplanted using HLA-matched sibling donors after conditioning with cyclophosphamide (CY), procarbazine (PCB), and ATG. Graft failure occurred in 16 of the eligible 113 patients, and with a median follow-up of 30 months (range, 1-80), probability of overall rejection was 15%. Specifically, the multitransfused patients who received high doses of stem cells with T-cell depletion showed the lowest rejection rate, 5.6%, compared with 30.3% in multitransfused patients with bone marrow stem cells alone (P ¼ 0.0310). Disease duration (P ¼ 0.0338) and the number of infused CD34+cells (P ¼ 0.0101) were associated with a high risk of graft rejection on multivariate analysis. ABO mismatch and the number of CD34+ cells were significant factors in the incidence of acute graft-versus-host-disease (GVHD). The incidence of chronic GVHD among patients with sustained engraftment was 13/109 (11.9%). With the same follow-up period, probability of disease-free survival for the entire group of patients at 6 years was 89% and the only factor associated with long-term survival was rejection (P ¼ 0.0241). These results suggest that allogeneic HSCT conditioned with triple agent immunosuppression, and specifically with high-dose stem cell return is probably an effective treatment for successful engraftment in SAA patients with a high risk of rejection. Bone Marrow Transplantation (2003) 31, 79-86. doi:10.1038/sj.bmt.1703786 Keywords: HSCT; SAA; rejection; transfusion; procarbazine Acquired aplastic anemia is one of several life-threatening marrow failure disorders. 1 The introduction of immunosuppressive therapy improved the prospects for severe aplastic anemia (SAA) patients. 2, 3 Furthermore, the results of allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched sibling donors, for patients with acquired SAA, have improved markedly since the late 1970s. [4] [5] [6] [7] [8] [9] [10] [11] [12] Allogeneic HSCT, with an appropriate conditioning regimen, has been able to cure around 90% of patients in recent times. 13, 14 However, graft failure following allogeneic HSCT remains a significant problem, and many factors such as disease duration, multiple transfusions and old age are associated with this complication. [15] [16] [17] Immunosuppressive treatment has been the mainstay for curing SAA, so that cyclophosphamide and antilymphocyte globulin (ALG) or antithymocyte globulin (ATG) have been used as effective therapies, which suggests, in part, an autoimmune basis for SAA. 18, 19 Other reports from several institutions used various transplant strategies to reduce graft failure rate. In spite of using a potent immunosuppressive conditioning regimen with high doses of hematopoietic stem cells for patients who were highly sensitized to alloantigens via prior multiple transfusion, substantial numbers of patients with graft failure have been reported. [20] [21] [22] We therefore, assessed our procarbazine (PCB)-containing conditioning regimen in patients with a long history of acquired SAA, including conditioning regimen those with multiple transfusion-associated alloantigens. This study is designed to investigate the results of HLA-matched sibling transplantation for SAA of duration with multiple blood product transfusions.
Materials and methods

Patients
A total of 113 patients treated for SAA between 1995 and 2001 in the Catholic Hemopoietic Stem Cell Transplantation Center were considered eligible for this study, if they had an HLA-identical sibling donor. In all cases, the etiology of the aplasia was unknown, and we excluded patients who had a PNH clone by flow cytometry since 1998. The median patient age was 28 (range, 16-50) and there were 61 males and 52 females. Median follow-up after allogeneic HSCT was 30 months (range, 1-80 months).
Time between diagnosis and transplant was a median of 16 months (range, 1-216 months). The median number of transfusions was 126 units of red blood cells7platelets (range, . When exact data were not available, the numbers of transfusions were documented so as to make a minimum estimate. We identified 58 multitransfused patients who had received more than 40 units of red blood cells7platelets. In all, 43 patients (38.1%) had been treated with ALG or ATG and androgen or combination therapy before allogeneic HSCT. SAA was diagnosed by standard criteria: (1) o25% cellularity, (2) 
Treatment schedule
Transplantation (Figure 1) All 113 patients received the same conditioning regimen consisting of cyclophosphamide (CY) 50 mg/kg/day once daily i.v. for 4 days (total dose 200 mg/kg), ATG 1.25 mg/ kg/day once every other day i.v. for 3 days (rabbit type, Pasteur Merieux, France), and procarbazine (PCB) 6.25 mg/kg/day p.o. in divided doses daily for 6 days. For graft-versus-host-disease (GVHD) prophylaxis, we used a combination of cyclosporine A (CsA) and short-term Table 1 Characteristics of patients according to stem cell source methotrexate (MTX). CsA was given as a continuous i.v. dose of 3 mg/kg/day until 21 days post-HSCT and then p.o. at 6 mg/kg/day, while MTX was given intravenously at a dose of 10 mg/m 2 on days 1, 3, 6, and 11. GVHD grading was according to the Seattle criteria.
Stem cell selection by T-cell depletion
We electively performed graft engineering in 43 patients (38.0%). In all, 19 patients (16.8%) received G-CSF primed bone marrow alone and the other 24 patients (21.2%) received fresh bone marrow plus PBSC CD34+ cells. G-CSF (10 mg/kg/day) was administered to donors by subcutaneous injection and continued for 5 days. Two leukaphereses were performed on days 5 and 6 of G-CSF administration. PBSC preparations were depleted of T lymphocytes using an immunoadsorption biotin-avidin column (Ceprate SC, Cell Pro, Bothell, WA, USA) in 14 patients. After January 1999, magnetic cell sorting was performed to purify PBSC with adequate recovery of CD34+ cells in the remaining 10 patients (CliniMACS system, Miltenyi Biotec, Bergisch Gladbach, Germany). BM harvesting was performed 48 h after the last leukapheresis at a volume of 15 ml per kg of recipient body weight. In all, 70 patients received bone marrow alone.
General supportive care
All patients were treated in single rooms with laminar airflow and received oral nonabsorbable antibiotics and a low microbial diet for gut decontamination. Trimethoprimsulfamethoxazole was administered for Pneumocystis carinii prophylaxis. Patients with an absolute neutrophil count (ANC) of less than 0.5 Â 10 9 /l and body temperatures exceeding 38.31C were empirically treated with broadspectrum antibiotics. Subcutaneous G-CSF (5 mg/kg/day) was started on the 7th day post-PBSC infusion and continued until the ANC reached 1.0 Â 10 9 /l for three consecutive days.
Engraftment
Time to hematopoietic recovery was measured as an ANC X0.5 Â 10 9 /l and a platelet count X20 Â 10 9 /l without platelet transfusion for 3 consecutive days. Engraftment was also assessed by routine marrow aspiration. Graft failure was defined as either primary graft failure, that is, absence of hematologic recovery in patients surviving X21 days after transplantation, or transient engraftment, that is, complete or partial recovery of hematopoiesis of donor origin followed by recurrent pancytopenia with a markedly hypocellular bone marrow in the absence of moderate-tosevere acute GVHD.
Statistical analysis
Actuarial probabilities of survival and graft failure were calculated using the Kaplan-Meier product-limit estimates. Patients surviving X30 and X100 days, with engraftment, were considered to be at risk of acute and chronic GVHD, respectively. Times to acute GVHD grades II-IV and chronic GVHD were calculated from the date of transplantation until occurrence of GVHD. Univariate analysis was performed to test associations between patient-, disease-and treatment-related variables and the probability of GVHD, graft failure and survival using the log-rank test. Factors associated with survival and graft failure in these Table 2 Results of allogeneic stem cell transplantation in three groups of severe aplastic anemia patients MNC: mononuclear cell; ANC: absolute neutrophil count; GVHD: graft-versus-host-disease. Graft rejection and death rate were relatively low in patients transplanted with a high dose of stem cells. However, incidences of AGVHD and CGVHD were high in the same group, although this was not statistically significant.
univariate analyses with a P-value o0.25 were used in a multivariate Cox proportional hazards regression analysis using a forward stepwise approach. A P-value o0.05 after multivariate analysis was considered to be statistically significant. Statistical analyses were performed using SAS for Windows (version 8e).
Results
Infused cell dose
The infused cell doses consisted of a median of 2.371.9(0.6-11.7) Â 10 Graft failure occurred in 16 of the 113 patients (14.1%) and the estimated probability of rejection was 15% (Figure 2a) . The onset of graft failure occurred at a median of 26 weeks after transplant (range, 1-80 weeks). The infused stem cell source was not the single most important factor in this analysis, but when we consider the multitransfused patients separately from the others, the lowest rejection incidence (5.6%) was observed in patients transplanted with a high dose of stem cells (n ¼ 20), compared with 30.3% in patients transplanted with bone marrow alone (n ¼ 30) (P ¼ 0.0310) and 13.1% in patients who were transfused with a small dose of bone marrow stem cells alone (Figure 2b) . Disease duration and the number of infused CD34+ cells were found to be associated with a high risk of graft rejection on multivariate analysis (Table 3) . Three patients had primary graft failure and 13 had transient engraftment with loss of the graft, nine patients with graft failure received booster therapy and eight patients remain alive with normal graft function. One patient who had a CVA died 8 months after booster therapy with a second rejection. G-CSF mobilized PBSC were used in seven patients and the other two patients received BM only. Preboost conditioning was with ATG, total nodal irradiation (TNI), or TNI plus corticosteroids (Table 4 ). Five of the seven patients who did not receive the booster donor cells after graft failure died, while the others remained alive on conservative therapy.
Overall survival was 89.5% (94/113) and the KaplanMeier estimate of a 6-year probability of disease-free survival was 89% (Figure 2c ). The survival rate was 72.0% for patients who experienced rejection and 93.5% for those without rejection from the whole study population (P ¼ 0.0043) (Figure 3 ). Survival differences were noted when we compared donor age (X29.2 vs o29. /kg CD34+ cells, P ¼ 0.0399, 0.0107, respectively), development of acute GVHD (P ¼ 0.0021), and chronic GVHD (P ¼ 0.0014). Of note, we found that the higher dose of stem cells necessary to promote better survival was in the range between 2.0 Â 10 6 /kg and 6.0 Â 10 6 /kg CD34+ cells. There were no marked gains in survival or in rejection incidence when patients received over 6.0 Â 10 6 /kg CD34+ cells. On univariate analysis, patient age, donor age, number of CD34+ cells, AGVHD, the occurrence of chronic GVHD, and rejection correlated with survival. Sex mismatch, interval from diagnosis to transplant (X16 vs o16 months), number of previous transfusions (X40 vs o40 units), and ABO mismatch did not significantly affect survival. On multivariate analysis, only rejection negatively influenced survival (P ¼ 0.0241) ( Table 5 ). Occurrence of chronic GVHD was significantly associated with survival (P ¼ 0.0651). We also compared survival rates between the three groups of patients stratified by stem cell source, that is, unmanipulated bone marrow alone (n ¼ 70), G-CSF primed bone marrow alone (n ¼ 19), and G-CSF primed bone marrow+PBSC CD34+ cells (n ¼ 24). We found no definite difference in probability of survival between the three groups ( Figure 4 ) and the results were similar when we separately compared probability of diseasefree survival in multiply-transfused patients of the three groups (data not shown). We considered this to be because of the relatively small sample numbers, especially in groups transplanted with G-CSF primed bone marrow and G-CSF primed bone marrow+PBSC CD34+ cells.
GVHD
Of the 113 patients at risk, 12 (10.5%) developed acute GVHD exceeding grade II. The incidence of chronic GVHD among patients with sustained engraftment was 13/109 (11.9%) and included eight limited and five extensive types. On multivariate analysis, statistically significant factors were ABO mismatch and number of CD34+ cells (Table 6 ). In one case, this was the primary cause of death. Six cases evolved from acute GVHD (progressive type). Donor age and the number of infused CD3+ cells were the factors associated with a marginal risk of chronic GVHD. Although the sample number was small, there was no statistically significant difference in the risk of AGVHD and CGVHD observed in patients who received high doses of stem cells compared with those who received bone marrow only (P ¼ 0.2208, 0.2660, respectively). 
Eight were treated successfully and are still alive after G-CSF mobilized PBSC in addition to the immunosuppression with ATG with or without total nodal irradiation. Three of seven untreated after graft failure died and the others are alive after other conservative therapies. 
Discussion
In this study, the overall estimated probability of rejection was 15% in patients who had received a triple immunosuppressive conditioning regimen including PCB, CY, and ATG. Patients whose transplant was performed for more than 16 months after diagnosis had a much higher rejection rate than other patients. Many patients could not obtain an early allogeneic HSCT in Korea. They had transfusions until they received notification from the national medical insurance system that is responsible for HSCT cover. More efficient conditioning regimens and high-dose stem cell therapy were started in the early 1990s. Several reports, including one from Seattle, presented the possible benefits of potent immunosuppression for HSCT with SAA. 7, 15, 23, 24 Many trials for the management of rejection and GVHD after allogeneic HSCT with SAA showed no significant survival improvement with the addition of radiation or ATG. 7, 25 Noticeably, the number of transfused units that can compromise the graft has yet to be clearly established, but a deleterious effect on engraftment and survival in heavily pretransfused allosensitized patients were found in this study (Tables 3 and 5) .
Our patients had long disease durations (median 16 months, range 1-216 months) and had received multiple transfusions. In addition, many of them (n ¼ 43) had ATG treatment before allogeneic HSCT. A total of 58 patients had been transfused with more than 40 units of RBC or platelets. It is for this reason that we attempted our triple immunosuppressive conditioning regimen, which was derived from a very old report dating from 1974 in Seattle, concerning the use of PCB or ATG associated with radiation-based regimens. 7 Many patients in this study received either only G-CSF primed bone marrow or high-dose stem cell component therapy, in an attempt to overcome graft rejection or to supply sufficient stem/ progenitor cells in cases of weight discrepancy between the donor and the recipient, in cases at a high risk of developing infections, and in cases where the donor are old. On comparing the two groups, that is, the multitransfused patients who received BM only and the patients who received a high dose of stem cells, we found no statistically significant differences in the frequencies of acute or chronic GVHD although the number of patients in this study was too small to allow any difference in the development of GVHD to be discovered. However, graft failure occurred in 30.3% of the multitransfused patients who received bone marrow alone compared to 5.6% of those who were transplanted with the same conditioning regimen and a high dose of stem cells derived from unmanipulated bone marrow plus T-cell-depleted PBSC. This difference points to the merit of high-dose stem cell transplantation for multitransfused patients. In addition, a more careful study is needed before adopting CD34-selected peripheral blood cells as the only transplant source in aplastic anemia patients because there has not been enough experience with blood stem cell allografting. 20 On the other hand, one interesting finding concerns CD34+ cell dose. Our data showed that the most effective CD34+ cell dose for disease-free survival, was between 2 Â 10 6 /kg and 6 Â 10 6 /kg, based on statistical analysis of survival benefit. We are unsure as to whether this result can be generalized to include all SAA patients. We reported some of these data earlier and assessed the benefit of high-dose stem cells to overcome a high risk of rejection because of previous multiple transfusions. [26] [27] [28] Our study is thus quite significant from the point of view of rejection following exposure to large amounts of alloantigens. Furthermore, our booster treatment for nine of 16 patients with graft failure was very effective and eight are alive with normal graft status. Two patients received more than just the second booster treatment, with variable preboost immunosuppression including ATG, total nodal irradiation or a combination, but in both cases this ended in failure. However, these two patients had a long disease duration, and had received many transfusions. For such patients, a different approach to the pathophysiology of SAA is needed, as well as consideration of minor histocompatibility antigen disparity between the patient and the donor.
In our study, based on multivariate analysis of the regression model, only rejection had a negative effect on survival, and chronic GVHD was associated with a low probability of survival. Specifically, chronic GVHD or acute GVHD are associated with decreased survival of SAA patients after allogeneic HLA-matched sibling transplant according to the Kaplan-Meier method of analysis. In this study, factors associated with acute GVHD were ABO mismatch and the number of infused CD34+ cells. Donor age and number of CD3+ cells were factors strongly associated with chronic GVHD. We believe T-cell depletion of PBSC by the CliniMACS method was effective in reducing development of chronic GVHD. As suggested by our data, it is well known that chronic GVHD is the major factor with a negative impact on survival. In line with this knowledge, our data on highdose stem cell infusion showed a somewhat increased incidence of acute GVHD (10 vs 22%) and chronic GVHD (18.5 vs 23.5%), although these results were not statistically significant.
This study is limited, given the small number of patients and the fact that there was no comparison with patients transplanted with conditioning regimens, excluding PCB or ATG. Of course, recent studies indicate that the addition of ATG to CY during conditioning leads to a low incidence of graft failure but we have to be very cautious in considering prior overexposure to transfusions and whether the low graft failure rates are the result of recent modifications in transfusion practice and general supportive care. Of note, although we would have obtained synergistic immunosuppressive effect between ATG and the alkylating agents, PCB and CY without a higher rate of complications, one case of thyroid papillary carcinoma occurred 3 years post-transplantation in this study. Therefore, our triple immunosuppressive regimen may increase the likelihood of long-term sequelae. However, in conclusion, HSCT using triple immunosuppressive therapy in SAA patients with an HLA-matched sibling donor, even after they have been multitransfused with a long disease duration was found to be an effective treatment. In addition, the successful booster treatment following graft failure in patients with SAA and the relatively low incidence of graft failure in these high-risk patients suggest that our strategy has the merit of sparing them from certain post-transplant complications.
